With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
The drug will be available in 600 hospitals and 105 DTPs
It is developing the drug candidate to potentially treat immunological diseases
In clinical trials, treatment proved more effective than other therapies evaluated
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The plan is to advance innovative therapies to drug-resistant cancers
Subscribe To Our Newsletter & Stay Updated
